Co-Authors
This is a "connection" page, showing publications co-authored by George Lau and Dong Ji.
Connection Strength
7.446
-
Reply to Grifoni et al. Clin Infect Dis. 2021 01 23; 72(1):183.
Score: 0.925
-
Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19. Metabolism. 2021 02; 115:154437.
Score: 0.914
-
Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues". J Hepatol. 2021 02; 74(2):484-485.
Score: 0.911
-
Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int. 2020 Sep; 14(5):701-710.
Score: 0.895
-
Reply to: 'NAFLD or comorbidities, that is the question'. J Hepatol. 2020 09; 73(3):724-725.
Score: 0.882
-
Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'. J Hepatol. 2020 09; 73(3):722.
Score: 0.881
-
Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'. J Hepatol. 2020 09; 73(3):718-719.
Score: 0.881
-
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020 08; 73(2):451-453.
Score: 0.876
-
Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020 09 12; 71(6):1393-1399.
Score: 0.226
-
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020 Sep; 14(5):690-700.
Score: 0.056